Skip to content

Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin

Non-interventional Trial to Investigate the Change of Psychopathological Markers of Affective Dysregulation (AD) in Children With Attention Deficit Hyperactivity Disorder (ADHD) Treated by Guanfacin, a Pilot Trial

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04016207
Enrollment
40
Registered
2019-07-11
Start date
2020-04-01
Completion date
2021-06-30
Last updated
2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Affective Dysregulation

Brief summary

Early onset, high prevalence and persistence, as well as developmental comorbidity make affective dysregulation (AD) in childhood one of the most psychosocially impairing and cost-intensive mental conditions. Despite continuous research, there is still a substantial need for optimization of individual treatment strategies in order to improve outcomes and to reduce subjective and economic burden. Here we want to study the change of psychopathological markers of affective dysregulation (AD) treatment of affective dysregulation (AD) in children with Attention Deficit Hyperactivity Disorder (ADHD) treated by Guanfacine. These children did not respond to methylphenidate treatment. The results will allow the generation of a hypothesis for a randomized clinical trial to investigate the efficacy and safety of Guanfacine for the treatment of AD in children.

Interventions

DRUGGuanfacine

regular treatment

Sponsors

Prof. Dr. Veit Roessner and PD Dr. Robert Waltereit jointly lead and conduct the study
CollaboratorUNKNOWN
Technische Universität Dresden
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* male and female patients (aged 6 to 17 years) * clinical diagnosis of ADHD (F90.0) or comorbid ADHD and Oppositional defiant disorder (ODD) (F90.1) * patients with ADHD who did not respond to stimulants * DADYS is an instrument to assess AD and has a domain for disruptive behaviors. Inclusion criterion for the study is a score of at least moderate (middle) severity in the DADYS parents version this domain * IQ must be at least 70 * Patients receiving or intended to receive Guanfacin * Written informed consent by the custodian and the children

Exclusion criteria

* unipolar depression, bipolar disorder, schizophrenia or any other psychotic disorder * current substance abuse

Design outcomes

Primary

MeasureTime frameDescription
DADYS-EF (Diagnostikum für Affektive Dysregulation, Eltern-Fragebogen)9 weeksThe DADYS is a German instrument to assess affective dysregulation. The Eltern-Fragebogen is the parents' version of the rating scale.

Secondary

MeasureTime frameDescription
DADYS-KF (Diagnostikum für Affektive Dysregulation, Kinder-Fragebogen)9 weeksThe DADYS is a German instrument to assess affective dysregulation. The Kinder-Fragebogen is the childrens' version of the rating scale.
Conners3L9 weeksThe Conners 3rd Edition™ (Conners 3®) is a thorough assessment of attention-deficit/hyperactivity disorder (ADHD) and its most common comorbid problems and disorders in children and adolescents aged 6 to 18 years. It is a multi-informant assessment that takes into account home, social, and school settings, with rating forms for parents, teachers, and youth.

Contacts

Primary ContactRobert Waltereit, MD
robert.waltereit@uniklinikum-dresden.de+493514582244

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026